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Abstract : The obesity epidemic is a global public health concern that increases the likeli-
hood of morbidity and mortality of metabolic and cardiovascular disease (CVD) and threat-
ens to reduce life expectancy around the world. The concept of the metabolic syndrome
(MetS) takes into account that visceral fat plays an essential role in the development of
metabolic and cardiovascular diseases. However, MetS cannot be used to assess global CVD
risk but is at best one more modifiable CVD risk factor. Thus, global cardiometabolic risk
(the global risk of cardiovascular disease resulting from traditional risk factors combined
with the additional contribution of the metabolic syndrome and/or insulin resistance)
should be considered individually. There is solid evidence supporting the notion that ex-
cess abdominal fat is predictive of insulin resistance and the presence of related metabolic
abnormalities currently referred to as MetS. Despite the fact that abdominal obesity is a
highly prevalent feature of MetS, the mechanisms by which abdominal obesity is causally
related to MetS are not fully elucidated. Besides visceral fat accumulation, ectopic lipid
deposition, especially in liver and skeletal muscle, has been implicated in the pathophysiol-
ogy of diabetes, insulin resistance and obesity-related disorders. Also, ectopic fat deposi-
tion could be deteriorated in the heart components such as (1) circulatory and locally re-
cruited fat, (2) intra- and extra-myocellular fat, (3) perivascular fat, and (4) pericardial fat.
In this review, the contribution of ectopic lipid deposition to global cardiometabolic risk
is reviewed and also discussed are potential underlying mechanisms including adipocy-
tokine, insulin resistance and lipotoxicity. J. Med. Invest. 60 : 1-14, February, 2013
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The obesity epidemic is a global public health
concern that increases the likelihood of morbidity
and mortality of metabolic and cardiovascular dis-
ease (CVD) and threatens to reduce life expectancy
around the world (1-2). The concept of the meta-
bolic syndrome (MetS) takes into account that vis-
ceral fat plays an essential role in the development
of metabolic and cardiovascular diseases (3-5).
MetS is merely a modifiable CVD risk factor as well
as traditional risk factors such as LDL-cholesterol,
diabetes, hypertension and smoking, but accounts
for a great proportion of mechanisms under the
obesity endemic era. Thus, global cardiometabolic
risk (the global risk of cardiovascular disease re-
sulting from traditional risk factors combined with
the additional contribution of the metabolic syn-
drome and/or insulin resistance) should be consid-
ered individually (6-8). Despite the fact that abdomi-
nal obesity is a highly prevalent feature of MetS,
ectopic fat deposition, especially in liver and skele-
tal muscle, has been implicated in the pathophysi-
ology of diabetes, insulin resistance and obesity-
related disorders (Fig. 1) (6-8). Also, ectopic fat
deposition in the cardiovascular components is now
recognized as a new cardiometabolic risk marker,
as it is associated with increased insulin resistance,
visceral fat and, in general, with the metabolic syn-
drome (6, 9-11). In this review, the contribution of
ectopic fat deposition to global cardiometabolic risk
and its potential underlying mechanisms are re-
viewed.
1. CONTRIBUTION OF ECTOPIC FAT
DESPOSION TO CARDIOVASCULAR DIS-
EASE
The amount of adipose tissue, as well as its dis-
tribution, is of special importance in the pathogene-
sis of insulin resistance and type 2 diabetes. Visceral
adipose tissue is metabolically highly active (3-5)
and its major role in the pathogenesis of insulin
resistance is widely accepted. Simultaneously, lipids
in ectopic (non-adipose) tissues such as liver and
skeletal muscle are of increasing interest. Liver fat
is elevated in insulin-resistant subjects (12, 13) and,
furthermore, is strongly correlated with the amount
of visceral fat in a prediabetic population (14). In
addition, high intramyocellular fat is a marker of
insulin resistance (15, 16). Thus, determination of
fat in the visceral depot and in the ectopic tissues
liver and muscle is thought to be a predictor for
subjects who are insulin resistant and have a high
risk of type 2 diabetes and cardiovascular dieases
(Fig 2). Recenlty, we evaluated the relationship be-
tween hepatic and muscular lipid deposition and vis-
ceral fat accumulation in middle-aged Japanese men
with MetS and found that visceral fat accumulation is
accompanied by excess lipid deposition in skele-
tal muscle (iliopsoas muscle, back muscle, rectus
Fig. 1. Ectopic fat deposition rather the whole-body fat distribution causes insulin resistance and vascular failure.


































abdominis muscle) and the liver (17). Interstingly,
changes in lipid contents by atnti-diabetic medica-
tions were different in the tissues (visceral fat
liver fatmuscle fat), suggesting that ectopic fat
desposion is regulated differently in these tissues.
Contribution of ectopic fat desposion to cardiovas-
cular disease are discussed below.
1.1. Coronary heart diseases
In the INTERHEART study (18), Yusuf et al. re-
ported the effect of various measures of adiposity
on rates of acute myocardial infarction (AMI) by
comparing 12,461 AMI cases and 14,637 standard-
ized-controls of variable ethnicity from 52 countries.
BMI showed a modest association with AMI (un-
adjusted odds ratio [OR] 1.44 for the top quintile
vs. the bottom quintile), but this association was
lost after adjustment for other risk factors. Mean-
while, adjusted OR for quintile of waist-to-hip ratio
was consecutively higher than that of the previous
one (OR 1.15 ; 1.39 ; 1.90 ; and 2.52, respectively).
Targher et al. assessed prospectively whether
Nonalcoholic fatty liver disease NAFLD, a typical
phenotype of ectopic fat deposition, predicts future
CVD events including nonfatal coronary heart dis-
ease (myocardial infarction and coronary revascu-
larization procedures), ischemic stroke, or cardio-
vascular death, among type 2 diabetic individuals
(19). After adjustment for age, sex, smoking his-
tory, diabetes duration, HbA1c, LDL cholesterol,
liver enzymes, and use of medications, the presence
of NAFLD was significantly associated with an in-
creased CVD risk (odds ratio 1.84, P0.001). Ad-
ditional adjustment for the metabolic syndrome ap-
preciably attenuated, but did not abolish, this asso-
ciation (1.53, P=0.02).
One form of ectopic fat deposition, epicardial adi-
pose tissue (EAT), is correlated with various car-
diovascular risk factors, independent of abdominal
visceral adiposity, body mass index (BMI), hyper-
tension, and diabetes mellitus (9-11). Two popu-
lation-based studies, the Multi-Ethnic Study of
Atherosclerosis and the Framingham Heart Study,
showed that EATV is an independent risk predictor
for cardiovascular disease (20, 21). EAT is shown
to be metabolically active and the source of pro-
atherogenic mediators and adipocytokines. We (22)
and others (23) showed that proinflammatory cytoki-
nes and adipocytokines are expressed and secreted
at a higher level in the adipose tissue of individuals
with coronary artery disease (CAD) than in indi-
viduals without CAD. Abdominal fat distribution is
dissimilar between men and women : Visceral fat
obesity is the dominant form in men, while subcu-
taneous fat obesity is the dominant form in women
(24, 25). We evaluated gender disparities in EATV
and its impact on coronary atherosclerosis by us-
ing multi-detector computed tomography (MDCT)
(Fig. 3). EATV/body surface area (BSA) was higher
among men in the CAD group than in the non-CAD
Fig 2. Ectopic fat deposition causes metabolic derrangements and cardiovascular diseases
Visceral fat obesity rather than subcutaneous fat obesity leads to lipid (free fatty acid) spreading to end-organs, causing ectopic fat
deposition and resultant insulin resistance via lipotoxicity mechanism(s)). Vascular failure is a consequence of insulin resistance/
glucose intolerance. Generalized lipodystrophy, genetic or acquired disorders without capacity to store fat in adipose tissue, shows
lipotoxic damage such as severe insulin resistance and vascular failure.
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group (6213 vs. 3310 cm3/m2, p0.0001), but
did not differ significantly among women in the 2
groups (4918 vs. 429 cm3/m2, not significant)
(26). Multivariate logistic analysis showed that
EATV/BSA was the single predictor for50% coro-
nary luminal narrowing in men (p0.0001). Thus,
increased EATV might be strongly associated with
coronary atherosclerosis only in men (26).
1.2. Cardiac dysfunction and heart failure
Echocardiographical measures of left ventricu-
lar (LV) structure and LV function were altered in
metabolic syndrome (27). Patients with metabolic
syndrome appeared more likely to show LV diastolic
dysfunction, independently of LV mass (27). Thus,
Veglobal, an index of global LV relaxation function,
decreased progressively from absent group (0 of
metabolic syndrome component), pre-metabolic
syndrome group (1-2 component), to metabolic syn-
drome group (=3 component), even after adjust-
ment for LV mass (27). In patients hospitalized for
CHF, 30%-40% present only with LV diastolic dys-
function but not with LV systolic dysfunction (28).
The presence of metabolic syndrome provides im-
portant risk information beyond that of established
risk factors also for congestive heart failure (CHF).
In a community-based sample of middle-aged men,
BMI and/or metabolic syndrome was a significant
predictor of CHF, independent of established CHF
risk factors (hypertension, T2DM, LV hypertrophy
and smoking) (29). There is strong evidence for
lipotoxic mechanisms in rodents showing that lipid
accumulation in the heart leads to heart failure. 1H-
MRS has been adapted to quantify lipid content in
cardiac muscle of human subjects (30), showing that
triglyceride (TG) was detectable in the myocardium
of healthy human subjects even in those who are
very lean. In overweight subjects myocardial TG
content was elevated and was accompanied by in-
creased left ventricular mass and a subtle reduc-
tion of septal wall thickening, which represents
mild systolic dysfunction (30). Myocardial fat was
found to be higher in obese than in lean subjects
and myocardial fat correlated with FFA levels,
epicardial fat, and waist-to-hip ratio (31). Epicardial
fat was positively associated with peripheral vascu-
lar resistance and negatively with the cardiac in-
dex. Combined, the cardiac accumulation of TG is
related to FFA exposure, generalized ectopic fat
excess, and peripheral vascular resistance and that
these changes precede left ventricular overload and
hypertrophy (32).
1.3. Cerebrovascular diseases
In the Atherosclerosis Risk in Communities
(ARIC) study, which included 14,448 men and
Fig 3. Men with coronary atherosclerotic disease (CAD) showed an increase in epicardial adipose tissue (EAT) volume
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women, Ohira et al. determined contribution of risk
factors on ischemic stroke subtype (33). In addi-
tion to traditional risk factors such as hypertension,
current smoking and T2DM, waist-to-hip ratio was
associated with increased risk for nonlacunar and
cardioembolic stroke, but not with lacunar stroke.
The population-attributable fraction for hyperten-
sion was approximately 35% for all ischemic stroke
subtypes. The each population-attributable fraction
for T2DM, current smoking, and waist-to-hip ratio
were 26.3%, 22.0% and -5.6% for lacunar ; 11.3%,
11.4%, and 9.7% for nonlacunar stroke ; 16.4%, 20.7%
and 2.9% for cardioembolic stroke. In Japanese popu-
lation of the Hisayama Study, the multivariate-ad-
justed incidence of non-ischemic and ischemic
stroke appeared higher in subjects with metabolic
syndrome in men (hazard ration [HR] 1.68, p=0.06
and 2.54, p=0.02) and women (1.78, p=0.01 and
0.99, p=0.91), as compared with those without meta-
bolic syndrome (34).
1.4. Atrial fibrilation, arrhythmic events and sudden
death
In the Paris Prospective Study I, which investi-
gated mortality of 6,678 middle-aged men, sagittal
abdominal diameter, substituted for waist circum-
ference, and the presence of metabolic syndrome
were associated with an increase in 1 hour sud-
den death (multivariate adjusted HR, 2.26 and 2.02),
so as with non-sudden death from AMI (HR 1.69
and 1.60) (35). Sudden death could be coming from
arrhythmic events including lethal ventricular fib-
rillation, since patients with metabolic syndrome had
significantly higher values of corrected QT interval
(QTc) and QT dispersion (QTd) on electrocardio-
gram, which reflects myocardial refractoriness and
electrical instability (36). In the Multicenter Auto-
matic Defibrillator Implantation Trial II (MADIT-
II) study (37), obesity (BMI =30 kg/m2) was a
risk factor for sustained ventricular tachyarrhythmia
in patients after myocardial infarction with severe
left ventricular dysfunction (LV ejection fraction
30%).
In analysis of Japanese 592 hospitalized patients
without obvious structural heart diseases (38), the
metabolic syndrome was a significant risk factor for
paroxysmal atrial fibrillation/flutter, independently
of left atrial diameter (44 mm) or age (70 years)
(OR 2.8, p0.01). In a community -based cohort
in Japan (28,000 subjects), Watanabe et al. dem-
onstrated an apparent correlation between the
presence of metabolic syndrome and increased
susceptibility to atrial fibrillation (39). Among the
metabolic syndrome components, obesity (BMI =
25) (age- and sex-adjusted HR, 1.64), as well as ele-
vated blood pressure (systolic pressure =130
mmHg and/or diastolic pressure = 85 mmHg)
(HR 1.69), low HDL-cholesterol (HR 1.52), and high
fasting plasma glucose (=110 mg/dL) (HR 1.44),
showed an increased risk for atrial fibrillation (39).
The association between the metabolic syndrome
and atrial fibrillation remained significant in subjects
without treated hypertension or T2DM (HR 1.78).
Obesity and metabolic syndrome were also shown
to be independent risk factors for atrial fibrillation
after coronary artery bypass graft surgery (40).
Whether the increased atrial fibrillation risk in meta-
bolic syndrome is due to the syndrome as a whole
or simply the sum of the risks of its individual
components is currently equivocal. A recent report
showed that EAT volume measured by MDCT was
highly associated with AF, independent of traditional
risk factors including left atrial (LA) enlargement
(41). A large sample from the Framingham Heart
Study (n=3,217) has shown that pericardial fat vol-
ume was associated with AF even after adjustment
for risk factors, including body mass index (42).
Nakanishi et al. also demonstrated that the peri-
atrial EAT volume predicted future AF events more
accurately than total EAT volume during follow-up
of 3.31.0 years (43). These results suggest the
potential role of peri-atrial EAT in the development
of AF such as local and direct effects on LA struc-
tures, generation of inflammatory cytokines, and
modulation of the intrinsic autonomic nervous sys-
tem.
1.5. Peripheral arterial disease
There are few studies examining the relationship
between obesity and peripheral arterial disease
(PAD). Whether obesity is a risk factor for devel-
opment of PAD remains controversial (44, 45). The
discrepancy may be due to the higher prevalence
of PAD in elderly males and in smokers ; elderly
males show a weaker relationship between obesity
and CVD, and smokers tend to have lower BMI
than non-smokers (46). A recent prospective cohort
study revealed a positive relationship between waist-
to-hip ratio, not BMI, and PAD prevalence (47).
Mechanisms by which obesity causes PAD (if any),
could be different to CHD, two do have different
risk profiles ; e.g. cigarette smoking is more strongly
associated with development of PAD than CHD
(48). Studies should be done to clarify effects of
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obesity on onset of PAD, complications such as
rupture of aortic aneurysm and severity of limb
ischemia.
1.6. Venous thromboembolism
Numerous studies have shown a clear relation-
ship between obesity and the risk of idiopathic ve-
nous thromboembolism (deep vein thrombosis and
pulmonary embolism), independent of other tradi-
tional risk factors (48, 49). In a study from Sweden,
men with a waist circumference=100 cm had a 4-
fold higher risk of venous thromboembolism than
with100 cm (49). Obese patients have chronically
raised intra-abdominal pressure and decreased
blood velocity in the common femoral vein. Inac-
tivity, poor gait, as well as other co-morbidity may
collectively impair venous return from the lower
limbs. Alternatively, obesity, in particular visceral
obesity, may have prothrombotic propensity via
mechanisms including : actions of adipocytokines,
increased activity of the coagulation cascade and
decreased activity of the fibrinolytic cascade, inflam-
mation, oxidative stress, endothelial dysfunction, and
disturbances in lipids and glucose homeostasis (50).
2. MECHANISTIC LINK BETWEEN ECTOPIC
FAT DESPOSION AND CARDIOVASCULAR
DISEASE
2.1. Adipocytokine and insulin resistance
There is solid evidence supporting the notion that
excess abdominal fat is predictive of insulin resis-
tance and of the presence of related metabolic ab-
normalities currently referred to as the metabolic
syndrome (3-8). Despite the fact that abdominal
obesity is a highly prevalent feature of the metabolic
syndrome, the mechanisms by which abdominal
obesity is causally related to the metabolic syndrome
are not fully elucidated. When categorized by whole-
body distribution of adiposity, insulin sensitivity is
well explained by ectopic fat deposition in insulin-
sensitive non-adipose tissue (Fig. 1, 3). Obese sub-
jects constantly deliver more lipids and dysregulated
adipocytokine than normal lean subjects ; visceral
fat obese can produce more pro-atherogenic adi-
pocytokine including free fatty acid (FFA) than
subcutaneous fat obese. Adipose tissue is not only
an energy storage tissue, but also a metabolically
active organ secreting hormones, cytokines and
growth factors, collectively called as adipocytokine
(adipokine), that act in an autocrine, paracrine or
endocrine manner (3-8). It is believed that anti-
atherosclerotic adipocytokine such as leptin and
adiponectin and pro-atherosclerotic cytokines such
as interleukin-6 (IL-6) and tumor necrosis factor α
(TNFα) cooperatively regulate metabolic and car-
diovascular homeostasis at local and remote site
(Table) (3-8, 51). Obesity and atherosclerotic proc-
ess at least partly share an inflammatory etiology
(52, 53), which hypothetically causes imbalance in
the interaction between nitric oxide (NO) and re-
active oxygen species (ROS) and result in a pro-
atherogenic vascular bed (54).
Comorbidity of hypertension, glucose intolerance
and dyslipidemia individually may cause cardiac
dysfunction directly via impaired relaxation of LV
and/or via vascular failure (endothelial dysfunction)
(55). The excess production of ROS may elicit tis-
sue damage in the heart, as shown in experimen-
tally induced-heart failure model (56). ROS could
be involved in the pathophysiology of human CHF
(57). Systemic oxidative stress is enhanced in
obese animals and in humans with visceral obesity
(58) or the metabolic syndrome (59). ROS derived
from visceral fat could affect LV geometry and LV
function.
2.2. Lipotoxicity
Obesity is associated with lipid accumulation
not only in adipose tissue, but also in non-adipose
tissues (60). The latter is known as ectopic fat depo-
sition and lipotoxicity, which is theorized to produce
obesity comorbidities such as insulin resistance,
T2DM and cardiovascular disease (Fig. 3). We first
described this concept in pancreatic β cells (β cell-
lipotoxicity) (61-63) and expand this to other tissues
including the heart (64, 65). As obesity develops,
insulin secretion increases parallel to insulin resis-
tance in order to maintain normal glucose homeo-
stasis. Patients predisposed to diabetes, however,
fail to compensate for greater insulin requirements,
and develop T2DM (60).
The remarkable hyperlipolytic activity of the vis-
ceral adipose tissue, over the subcutaneous adipose
tissue, contributes to exposure the liver, skeletal
muscle and even the cardiovascular system to ex-
cess FFA. This impairs insulin-dependent metabolic
process, and leads to hyperinsulinemia, glucose in-
tolerance (an increase in hepatic glucose production
and decreases in skeletal and hepatic glucose up-
take), hypertriglyceridemia (an increase in VLDL-
apolipoprotein B secretion), low plasma HDL-cho-
lesterol level, and cardiovascular disturbance (60).
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2.3. Cardiac adiposity and epicardial fat : cardiac
lipotoxicity
Mechanisms by which abdominal adiposity im-
duces cardiac dysfunction remain unknown (27-
32). From evidence described here, one of authors
(MS) previously proposed an idea that ectopic fat
deposition in the heart is causally related to car-
diac performance and structural remodeling at multi-
ple component by (A) circulatory and locally-re-
cruited fat (66), (B) intra- and extra-myocellular fat
(64, 65), (C) perivascular fat (67-69), and (D) peri-
cardial fat (6-11), collectively to be called ”cardiac
lipotoxicity”.
2.3.1. Circulatory and locally-recruited fat (Vascu-
lar lipotoxicity)
An oversupply of FFA to the bloodstream from
visceral adipose tissues may disturb vascular homeo-
stasis. We found a ”vascular lipotoxicity” phenome-
non that FFA does directly activate vascular ROS
production and leads endothelial dysfunction in
obese model (66). Circulating FFA can acutely in-
crease vascular ROS signals and chronically enhance
vascular expression of NADPH oxidase multisubunit
complex, which is the major source of superoxide
anion in the vasculature (70, 71). Two general
mechanisms underlying activation of NADPH oxi-
dase are either an acute increase in oxidase com-
plex formation secondary to post-translational modi-
fication of regulatory subunits or mitochondrial un-
coupling (72, 73), or a chronic increase in the ex-
pression and abundance of component subunits (70,
71). The locally produced ROS (66) and fat-de-
rived ROS (58) simultaneously react with NO, gen-
erate peroxynitrite, and finally impair cGMP-de-
pendent vasodilatation.
2.3.2. Intra- and extra-myocellular fat
Contents of intra- and extra-myocellular fat are
shown to be closely related to visceral fat adiopos-
ity in animal model (64, 65) and in human (69). Fat
accumulation of the myocardium is associated with
LV hypertrophy and dysfunction that ultimately pro-
gresses to lipotoxic heart disease (64). Myocardial
fat accumulation and lipotoxic cardiomyopathy in
this model can be prevented by an insulin sensitizer
treatment initiated at an early age (60). In human,
Szczepaniak et al. showed that the contractile func-
tion of myocardium measured by MRS was nega-
tively correlated with myocardial TG levels (69),
and also found that elevated myocardial TG levels
developed LV concentric hypertrophy. This obser-
vation suggests that high myocardial TG levels her-
ald contractile dysfunction in humans.
2.3.3. Perivascular fat
Perivascular fat is another candidate of mediator
for obesity-associated cardiovascular risk. It is de-
fined as the accumulation of fat around vascular
structures, mostly in the proximity of all blood ves-
sels and around the coronaries and the aorta. Con-
ventionally, perivascular fat was considered to act
largely as a structural support for vasculature. Re-
cent experimental data from ex-vivo epicardial adi-
pose tissue and arteries suggest that periadventitial
fat can modulate vascular responsiveness to vasoac-
tive agents (55, 56) (68-70). Perivascular fat can
secrete a variety of cytokines and chemokines and
could contribute to the pathogenesis and/or pro-
gression of obesity-induced atherosclerosis.
2.3.4. Pericardial fat
Accumulation of excess pericardial fat, which
shares the capacity to secrete cytokines with vis-
ceral fat might be related to cardiac remodeling (6-
11). Its quantity is well correlated with the mass of
visceral adipose tissue. Human pericardial adipose
tissue has a considerable secretory activity ; epicar-
dial adipose tissue from patients undergoing elec-
tive coronary aortic bypass grafting contained more
mRNA and protein for IL-1β, IL-6, monocyte
chemoattractant protein 1 (MCP-1) and TNFα com-
pared to subcutaneous adipose tissue (22, 23). In
pericardial tissue, the cytokine concentrations were
correlated well with an accumulation of inflamma-
tory cells, such as T-lymphocytes, macrophages
and mast cells. Adiponectin might also play a role
in pericardial adipose tissue, as patients with ad-
vanced coronary heart disease have lower level of
epicardial adiponectin. A recent clinical study
showed that pericardial adipose tissue represents
a novel indicator of cardiovascular risk (20, 21).
3. MANAGEMENT STRATEGY FOR GLOBAL
CARDIO-METABOLIC RISK
3.1. Individual risk factors and global cardio-meta-
bolic risk
Although remarkable progress has been made
in the management of traditional CVD risk fac-
tors such as hypertension, elevated LDL-choles-
terol, smoking, and diabetes mellitus, approach to
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abdominal obesity/metabolic syndrome have not
been reached to a worldwide consunsus (7, 8, 74).
The American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD) as well as the International Chair on Car-
diometabolic Risk have emphasized the critical im-
portance of first using global risk calculators such
as the Framingham risk score, the PROCAM algo-
rithm or the European SCORE (74, 75). However,
there is evidence to suggest that the risk assess-
ment algorithms may not accurately estimate the
global CVD risk in patients with visceral obesity/
metabolic syndrome. Thus, it is essential to de-
velop a risk assessment model of global CVD in
the presence of traditional risk factors and emerg-
ing markers found in individuals with visceral obe-
sity. Després et al. defined this model as global
cardio-metabolic risk (76). Under this model, car-
diometabolic risk is the global risk of CVD result-
ing from the presence of traditional risk factors
combined with the possible additional contribution
of the metabolic syndrome. Namely, the metabolic
syndrome cannot be used to assess global CVD
risk but is at best one more modifiable CVD risk
factor. To modify this model for clinical setting,
we propose cardiometabolic risk cascade causing
cardiovasuclar disease (Fig. 4).
It is also claimed that the Framingham risk score
does not properly assess lifetime risk particularly
among young adults or adolescents with abdomi-
nal obesity (77), which are not considered at a risk
of CVD by current algorithms because of young
age. Surrogate markers to detect abnormalities in
ROS and renin-angiotensin-aldosterone system
(RAAS), vascular failure (endothelial dysfunction),
neurohumoral stress and arrhythmogenicity could
have additional powers in long-term assessment of
global CVD risk.
3.2. Visceral fat management
Obesity management goals should encompass re-
duction in total cardiovascular morbidity and mor-
tality. Losing 5% to 10% of body weight reduces the
traditional CV risks (78). Increasing physical activ-
ity, in combination with a diet that emphasizes fresh
fruits and vegetables, whole grains, and low-fat dairy
products, can help patients reduce weight and obe-
sity comorbidity.
Less is known about the long-term effect of weight
loss on the development of T2DM and CVD out-
comes in the form of death, myocardial infarction,
and stroke. A trial to answer the most important
Fig 4. Cardiometabolic risk cascade causing cardiovascular disease
CVD, cardiovascular disease ; MetS, metabolic syndrome ; IGT, impaired glucose tolerance ; PPHG, postprandial hyperglycaemia
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question whether the improvements in cardiovas-
cular risk factors by managed weight loss will be
associated with reduction in long-term cardiovas-
cular events was investigated (The Look AHEAD
(Action for Health in Diabetes) trial) (79). The study
enrolled 5,145 people with type 2 diabetes and a
BMI greater than 25, randomizing half to a life-
style intervention and half to a general program of
diabetes support and education (80). Although those
in the intervention group kept off 5% of their initial
body weight at 4 years, there was no difference be-
tween them and the standard care group in the rate
of myocardial infarction, stroke, hospitalizations for
angina, and cardiovascular death -- the primary out-
come. Despite no reduction in cardiovascular events
in those in the intense intervention arm, they did
experience other health benefits. Patients in this
group saw improvements in sleep apnea and mobil-
ity, as well as quality of life. In addition, their dia-
betes medications were reduced. In addition, at 1
and 4 years, both diabetes control (glucose, HbA1c)
and most cardiovascular disease risk factors (blood
pressure, HDL cholesterol, triglycerides) were more
favorable in the lifestyle intervention than in the con-
trol group with the exception of LDL cholesterol,
which was not different between groups at year 1.
At year 4, those in the intensive lifestyle interven-
tion group continued to have more favorable dia-
betes control and CVD risk factor reduction, with
the exception of LDL-C in which there were slightly
greater reductions in the standard care group. Par-
ticipants in the lifestyle intervention group main-
tained greater improvements in fitness at both years
1 and 4.
According to AHA/ACCF Secondary Prevention
and Risk Reduction Therapy for Patients With Coro-
nary and Other Atherosclerotic Vascular Disease :
2011 Update : Intervention Recommendations With
Class of Recommendation and Level of Evidence
(Fig. 5) (81), weight management is recognized as
Fig 5. Body weight management : AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary
and Other Atherosclerotic Vascular Disease : 2011 Update : Intervention Recommendations With Class of Recommendation and
Level of Evidence
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Class I (Procedures/Treatment should be per-
formed/administered), but estimated of certainty of
treatment effect is named as Level B or Levels C.
When indicated, exercise, caloric intake, and formal
behavioral programs are recommended to main-
tain/achieve a body mass index between 18.5 and
24.9 kg/m2 (Level of Evidence : B), or to achieve
waist circumference (89 cm) in women and (102
cm) in men or to reduce body weight by approxi-
mately 5% to 10% from baseline.
CONCLUSION
The concept of the metabolic syndrome takes
into account the central role that visceral fat plays
essential role in the development of metabolic and
cardiovascular diseases, and indicates how waist
circumference measurement is useful in aiding pa-
tient identification in a clinical setting. The meta-
bolic syndrome cannot be used to assess global
CVD risk but is at best one more modifiable CVD
risk factor. Thus, global cardiometabolic risk should
be considered individually. Increased visceral fat
is associated with a shift in the normal balance of
the adipocytokines resulting in pro-inflammatory
and pro-atherosclerotic state. Although evidence for
therapeutic efficacy in the treatment of abdominal
adiposity and clustering of cardiometabolic risks
are limited, this should be a promising challenge
to reduce the highly contagious state around the
world.
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